Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Completed · Phase 2

Conditions studied: Cushing's Syndrome

In brief

The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.

Key facts

Study ID

NCT03606408

Run by

RECORDATI GROUP

People needed

127

Starts

2018-10-05

Expected to finish

2023-11-16

Last updated by the study team

2024-12-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is currently participating in a Global Novartis-sponsored study receiving osilodrostat for any type of endogenous CS and has fulfilled all their requirements in the parent study.
• Patient is currently benefiting from treatment with osilodrostat, as determined by the Investigator.
• Patient has demonstrated compliance, as assessed by the Investigator, with the parent study protocol requirements.
• Willingness and ability to comply with scheduled visits and treatment plans.
• Written informed consent obtained prior to enrolling into the roll-over study before evaluating the applicability of the subject's participating in the study. -- If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

You may not qualify if…

• Patient has been permanently discontinued from osilodrostat study treatment in a parent Novartis-sponsor study.
• Patients who are receiving osilodrostat in combination with unapproved or experimental treatments for any type of endogenous CS.
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Pregnant or nursing (lactating) women
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week of study after stopping medication. Highly effective contraception methods include:
• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation. at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
• Male sterilization (at least 6 months prior to baseline). The vasectomized male partner should be the sole partner for that subject
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.

Where it is running

• Emory University School of Medicine G2304 - C2301 — Atlanta, Georgia, United States
• Northwestern University SC - LCI699C2301 — Chicago, Illinois, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Columbia University Medical Center New York Presbyterian Neuroendocrine Unit — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Oregon Health and Science University — Portland, Oregon, United States
• University of Pennsylvania Medical Center Univ Penn — Philadelphia, Pennsylvania, United States
• Medical College of Wisconsin MCW 2 — Milwaukee, Wisconsin, United States
• Sanatorio Guemes — CABA, Buenos Aires, Argentina
• Universitaetsklinik fuer Innere Medizin III — Vienna, Austria
• Gasthuisberg University Hospital — Leuven, Belgium
• Universidade Federal do Ceara — Fortaleza, Ceará, Brazil
• Hospital Universitario Clementino Fraga Filho — Rio de Janeiro, Rio de Janeiro, Brazil
• Hospital do Servidor Publico Estadual de Sao Paulo — São Paulo, São Paulo, Brazil
• Hospital das Clinicas da Faculdade de Medicina da USP — São Paulo, São Paulo, Brazil
• USHATE Akad Ivan Penchev — Sofia, Bulgaria
• University of Alberta Hospital — Edmonton, Alberta, Canada
• QEII Health Sciences Centre — Halifax, Nova Scotia, Canada
• Centre de recherche du CHUM CRCHUM — Montreal, Quebec, Canada
• CHUS Hopital Fleurimont — Sherbrooke, Quebec, Canada
• The First Affiliated Hopsital, Sun Yat-Sun University — Guangzhou, Guangdong, China
• West China Hospital of Sichuan University — Chengdu, Sichuan, China
• Peking University First Hospital — Beijing, China
• University of Colorado — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.